Business
Clarivate Enhances Cortellis CMC Intelligence Platform with Addition of Comprehensive Biologics Content
Clarivate Enhances Cortellis CMC Intelligence Platform with Addition of Comprehensive Bio...
About this update from Carlyle Commodities Corp.
[{"type":"text","content":"\n \n \n \n Clarivate Enhances Cortellis CMC Intelligence Platform with Addition of Comprehensive Biologics Content\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Complete insights on biologic CMC requirements enable pharma, biotech and generics organizations to\n \n \n \n accelerate\n \n innovation by bringing life-saving medicines to patients faster\n \n \n \n \n LONDON\n \n ,\n \n Jan. 20, 2021\n \n /CNW/ --\n \n Clarivate Plc\n \n (NYSE: CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the enhancement of\n \n Cortellis CMC Intelligence\n \n ™, the world's only organized, timely and accurate source of Chemistry, Manufacturing and Controls (CMC) regulations and local practices. The addition of new biologic CMC content and features will support pharma, biotech and generics organizations in their quest to efficiently and accurately plan and prepare their CMC regulatory dossier submissions.\n \n \n During these unprecedented times, researchers across the healthcare continuum need to connect the dots across multiple data points to enable the development and distribution of life-saving therapies. Most urgently, drug developers need practical solutions to support the manufacturing and global distribution of novel COVID-19 vaccines. In this new age of expedited drug development, Cortellis CMC Intelligence is a single platform solution for efficient identification, tracking, and comparison of CMC requirements, for all drug types, across the globe.\n \n \n CMC and regulatory professionals are today challenged to find all necessary requirements for successful drug filings, culling through volumes of often regionalized and siloed data and insights. Critical pieces of information can be overlooked and result in delayed drug approvals and costly re-submissions. According to recent studies, 18% of total R&D expenditure is spent on CMC activities conducted to optimize, scale-up, and validate the processes and technologies...